טוען...

CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

Background: Targeting tumour necrosis factor α (TNF-α) has demonstrated efficacy in Crohn’s disease. Aim: To evaluate CDP571, a humanised antibody to TNF-α, for treating active Crohn’s disease. Patients: A total of 396 patients with moderate to severe Crohn’s disease. Methods: In a 28 week, randomis...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
Main Authors:	Sandborn, W J, Feagan, B G, Radford-Smith, G, Kovacs, A, Enns, R, Innes, A, Patel, J
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Copyright 2004 by Gut 2004
נושאים:	Inflammatory Bowel Disease
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC1774244/ https://ncbi.nlm.nih.gov/pubmed/15361500 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2003.035253
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

פריטים דומים